london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Intravitreal bevacizumab therapy for treatment of retinopathy of prematurity- experience in Jakarta eye center, Indonesia

Session Details

Session Title: Vascular Diseases and Diabetic Retinopathy II

Session Date/Time: Friday 12/09/2014 | 11:00-13:00

Paper Time: 11:56

Venue: Boulevard C

First Author: : F.Manurung INDONESIA

Co Author(s): :    G.A. Adriono              

Abstract Details

Purpose:

To determine the efficacy of intravitreal bevacizumab (IVB) in the treatment of retinopathy of prematurity (ROP) in Jakarta Eye Center.

Setting:

A retrospective case series study.

Methods:

This study included patients receiving one dose of intravitreal injections of bevacizumab (0.625 mg) for the treatment of ROP between 2008 and 2012. The effects (regression of ROP) and complications were analyzed.

Results:

Forty eyes of 21 infants were enrolled. The mean +/- SD gestational age was 29 +/- 4 weeks and mean +/- SD birth weight was 1,200+/- 400 grams, respectively. There were 14 eyes (7 patients) with Agressive Posterior ROP, 25 eyes (13 patients) with stage 3 ROP, and 1 eye (1 patient) with stage 4A ROP. The median injection time given was 6 weeks post menstrual age (range: 2-12 weeks). Nineteen eyes were given IVB as first-line treatment and 2 eyes as adjunctive to laser photocoagulation. Overall, 30 eyes (75%) have favourable outcomes after one injection of bevacizumab only (monotherapy). Six eyes required additional laser after IVB to achieve ROP regression, and 2 eyes were lost to follow up. No serious adverse events and reccurrences were noted.

Conclusions:

IVB is indicated to be effective in promoting regression of treatment-requiring ROP. Although IVB has become an increasingly popular therapy for ROP, long-term safety and effectiveness warrants further investigations/trials.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy